6160 Stock Overview
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.00 |
| 52 Week High | US$161.80 |
| 52 Week Low | US$75.45 |
| Beta | 0.63 |
| 1 Month Change | -4.97% |
| 3 Month Change | -9.98% |
| 1 Year Change | -42.04% |
| 3 Year Change | -54.55% |
| 5 Year Change | 15.08% |
| Change since IPO | -18.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6160 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 7.3% | 3.7% | 2.3% |
| 1Y | -42.0% | -41.4% | -10.9% |
Return vs Industry: 6160 matched the Hong Kong Biotechs industry which returned -41.4% over the past year.
Return vs Market: 6160 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 6160 volatility | |
|---|---|
| 6160 Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6160 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6160's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,600 | John Oyler | www.beigene.com |
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic.
BeiGene, Ltd. Fundamentals Summary
| 6160 fundamental statistics | |
|---|---|
| Market cap | HK$113.75b |
| Earnings (TTM) | -HK$6.91b |
| Revenue (TTM) | HK$19.26b |
5.9x
P/S Ratio-16.5x
P/E RatioIs 6160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6160 income statement (TTM) | |
|---|---|
| Revenue | US$2.46b |
| Cost of Revenue | US$543.47m |
| Gross Profit | US$1.92b |
| Other Expenses | US$2.80b |
| Earnings | -US$881.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -8.44 |
| Gross Margin | 77.90% |
| Net Profit Margin | -35.86% |
| Debt/Equity Ratio | 25.0% |
How did 6160 perform over the long term?
See historical performance and comparison